Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

Haemophilia

Volumn 14, Issue 4, 2008, Pages 671-684

  Keeling, D ^a,d   Tait, C ^b   Makris, M ^c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Haemophilia; Inherited bleeding disorder; Therapeutic; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BETAFACT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; FANHDI; FIBRINOGEN; FIBROGRAMMIN P; FRESH FROZEN PLASMA; HAEMOCOMPLETTAN; HEMOLEVEN; HEPATITIS A VACCINE; KOGENATE BAYER; OCTANATE; OCTANINE; OPTIVATE; PLACEBO; PROTHROMBIN COMPLEX; PROTHROMPLEX T; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; REPLENINE VF; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; WILATE; WILFACTIN;

ANAPHYLAXIS; ARTICLE; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL TRIAL; EVIDENCE BASED PRACTICE; FIBRINOGEN DEFECT; FLUSHING; GENETIC DISORDER; HEADACHE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFORMED CONSENT; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN DEFICIENCY; SIDE EFFECT; THROMBOSIS; UNITED KINGDOM; VACCINATION; VON WILLEBRAND DISEASE;

AUTOANTIBODIES; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTORS; BLOOD-BORNE PATHOGENS; COAGULANTS; EVIDENCE-BASED MEDICINE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; RECOMBINANT PROTEINS; THROMBOSIS; VIRUS INACTIVATION;

EID: 47649096167     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01695.x     Document Type: Article

References (49)

1. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
2. Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-84.
3. Santagostino E, Mannucci PM, Gringeri A et al. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 1994; 71: 737-40.
4. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
5. Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-31.
6. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
7. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13-23.
8. Lee CA. Transfusion transmitted disease. Bailliere's Clinical Haematology 1996; 9: 369-94.
9. Kessler CM. New perspectives in hemophilia treatment. Hematology/The Education Program of the American Society of Hematology American Society of Hematology 2005; 429-35.
10. Bolton-Maggs PH, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-33.
11. White B, Lawler P, Riddell A et al. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease. Br J Haematol 2004; 126: 100-4.
12. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-93.
13. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
14. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
15. Lee CA, Chi C, Pavord SR et al. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12: 301-36.
16. Sanchez-Luceros A, Meschengieser SS, Turdo K et al. Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. Thromb Res 2007; 120: 387-90.
17. Henry DA, Moxey AJ, Carless PA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No. CD001886. doi:.
18. Zufferey P, Merquiol F, Laporte S et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105: 1034-46.
19. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
20. Mohri H. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J Thromb Thrombolysis 2002; 14: 255-7.
21. Morimoto Y, Yoshioka A, Sugimoto M, Imai Y, Kirita T. Haemostatic management of intraoral bleeding in patients with von Willebrand disease. Oral diseases 2005; 11: 243-8.
22. Peerlinck K, Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet 1993; 341: 179.
23. Fischer G, Hoots WK, Abrams C. Viral reduction techniques: Types and purpose. Transfus Med Rev 2001; 15: 27-39.
24. Note for guidance on plasma derived medicinal products.: Committee for Proprietary Medicinal Products (CPMP). Document number CPMP/BWP/269/95 rev 3, 2001.
25. Gaboulaud V, Parquet A, Tahiri C et al. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: Results from the French haemophilia cohort. Br J Haematol 2002; 116: 383-9.
26. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M. Eliminating parvovirus B19 from blood products. Lancet 1994; 343: 798.
27. Knight R, Stanley S, Wong M, Dolan G. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost 2006; 32(Suppl 2): 3-9.
28. Fourth case of transfusion-associated vCJD infection in the United Kingdom. Euro Surveill 2007; 12: E070118-4.
29. Hewitt P. vCJD and blood transfusion in the United Kingdom. Transfus Clin Biol 2006; 13: 312-6.
30. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
31. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
32. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
33. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
34. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
35. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study. Blood 2007; 109: 4693-7.
36. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6): 102-6.
37. Warrier I. Factor IX inhibitor and anaphylaxis. Inhibitors in patients with haemophilia. Oxford: Blackwell Science, 2002: 87-91.
38. de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: A randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-22.
39. Goedert JJ, Cohen AR, Kessler CM et al. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet 1994; 344: 791-2.
40. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-9.
41. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96: 293-7.
42. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
43. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
44. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
45. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
46. McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336: 1137-8.
47. Carless PA, Henry DA, Moxey AJ et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews Art No: CD001884 2004.
48. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53.
49. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983; 309: 816-21.